Every day of delay in T1D progression matters to patients.
Get your whole MDT ready to deliver the first Tzield infusion with confidence in your service with this practical full- day training, from infusion setup to patient communication. Register below.
Dates: Fri 17th April | Tues 19th May | Mon 1st June | Wed 17th June
Who should come along?
For all healthcare professionals involved in the Teplizumab infusion delivery including the prescribing clinician(s), infusion pharmacist, diabetes specialist nurse(s) and infusion nurse(s). Teams do not need to attend the same day.
Infusion Training Information
Training Topics
Hands-on practice with actual infusion equipment and set up
Case-based learning following real patient journeys (pre/during/post infusion)
Connect with expert faculty including Prof. Parth Narendran, Dr Renuka Dias, and other leading speakers
Patient communication strategies for how to explain Tzield at diagnosis and beyond
Interactive Q&A throughout the day with continuous peer discussion to facilitate your learning
Speakers
The training will be delivered by a number of experts, including:
Prof Parth Narendran
Dr Renuka Dias
Prof Colin Dayan
Nomancia Vilanculo-Laita
More speakers to be announced soon!
Speakers may vary depending on date of training.
Logistics Information
This workshop is for HCPs in the UK who are planning on prescribing Tzield or involved in the preparation of Tzield. This promotional workshop series is funded by Sanofi. The educational content, speaker selection, and materials for this workshop series have been co-developed by an independent faculty of healthcare professionals, and Sanofi. All materials will have been reviewed by Sanofi for compliance purposes.
- This workshop is free to attend.
- You only need to attend one workshop.
- For those requiring air travel and/or accommodation, the costs of this may be funded by Sanofi.
- CPD accreditation will be applied for.
Get in Touch with Us
Questions? Leave your details and we'll reach out to you at your preferred time.
Get in touchINDICATION: TZIELD is indicated to delay the onset of Stage 3 T1D in adult and paediatric patients 8 years of age and older with Stage 2 T1D.1
MDT, multi-disciplinary team; T1D, type 1 diabetes
- TZIELD® (teplizumab) UK Summary of Product Characteristics. 2025.
MAT-XU-2600707 (v1.0) | April 2026